Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Z Rheumatol ; 79(10): 1057-1066, 2020 Dec.
Article in German | MEDLINE | ID: mdl-32040755

ABSTRACT

BACKGROUND: Raynaud's phenomenon and the frequently ensuing digital ulcerations represent an early and very distressing symptom in patients with systemic sclerosis (scleroderma, SSc) causing significant limitations in the ability to work and quality of life. The use of vasoactive drugs (especially intravenous prostacyclin derivatives) is recommended to reduce the risk of hypoxic tissue damage up to the loss of fingers. METHODS: In order to obtain information about the current state of treatment of patients with prostacyclin derivatives in routine clinical life in Germany, a survey was conducted among the centers affiliated to the German Network for Systemic Scleroderma (DNSS). In addition, a separate patient survey was conducted by the schleroderma self-help group (Sklerodermie Selbsthilfe e. V.), which only covered the symptoms Raynaud's syndrome, digital ulcers and the use of intravenous prostacyclin derivatives. RESULTS: Of the 433 patients surveyed 56% stated that they had already been treated with prostacyclin derivatives (iloprost/alprostadil) because of their illness and symptoms. A total of 61% received the treatment for severe Raynaud's phenomenon and 39% for digital ulcerations. Most respondents not only experienced an improvement in Raynaud's phenomenon and digital ulcers but also a significant improvement of limitations in everyday life. They also needed significantly less outside help and absenteeism from work was much lower. CONCLUSION: Patients consistently reported a positive effect of treatment with prostacyclin derivatives on Raynaud's phenomenon, acral ulcerations, pain and daily restrictions and felt well and safely cared for during inpatient treatment. These positive effects in the patients' perceptions provide crucial information supporting and confirming the current European and international treatment recommendations.


Subject(s)
Epoprostenol , Raynaud Disease , Scleroderma, Systemic , Epoprostenol/analogs & derivatives , Epoprostenol/therapeutic use , Fingers/blood supply , Germany , Humans , Inpatients , Quality of Life , Raynaud Disease/diagnosis , Raynaud Disease/drug therapy , Raynaud Disease/epidemiology , Scleroderma, Systemic/complications , Scleroderma, Systemic/diagnosis , Scleroderma, Systemic/drug therapy , Skin/blood supply
2.
Arthritis Care Res (Hoboken) ; 72(8): 1041-1048, 2020 08.
Article in English | MEDLINE | ID: mdl-31150152

ABSTRACT

OBJECTIVE: To determine the type and frequency of physical therapy (PT) prescribed by physicians for patients in the registry of the German Network for Systemic Sclerosis. METHODS: The data for 4,252 patients were analyzed using descriptive statistics, chi-square tests, and odds ratios (ORs). RESULTS: Overall, 37.4% of patients (1,590 of 4,252) received PT at the end of a yearly follow-up. The most frequently used type of PT was lymphatic drainage (n = 1,061, 36.8%), followed by exercise therapy (n = 1,047, 36.3%) and heat therapy (n = 689, 23.9%). More than three-fourths of treated patients (82%) received 1 or 2 different forms of PT simultaneously. The prescription of PT was associated with the extent of skin fibrosis as measured by the modified Rodnan skin thickness score (<10 [41.8% of patients], 11-20 [55.8% of patients], and >21 [63.9% of patients]; P < 0.001). Patients with musculoskeletal involvement (e.g., arthritis, muscle weakness, joint contractures, tendon friction rubs) had a higher chance of receiving PT than patients without these symptoms, with corresponding ORs ranging from 1.96 (95% confidence interval [95% CI] 1.69-2.28) for joint contractures to 3.83 (95% CI 2.89-5.08) for arthritis. When comparing the type of PT prescription across the initial and all follow-up visits from 2003 to 2017, significant alterations with a decreasing frequency of patients receiving PT could be observed (P = 0.001). CONCLUSION: To our knowledge, this is the first study reporting the use of PT in patients with systemic sclerosis (SSc) in a large cohort. Although SSc is characterized by considerable disability and restriction of motion, <40% of patients received PT.


Subject(s)
Patient Acceptance of Health Care/statistics & numerical data , Physical Therapy Modalities/statistics & numerical data , Scleroderma, Systemic/therapy , Severity of Illness Index , Chi-Square Distribution , Cohort Studies , Disability Evaluation , Female , Germany , Humans , Male , Middle Aged , Odds Ratio , Registries , Scleroderma, Systemic/pathology
3.
Z Rheumatol ; 68(2): 154-6, 2009 Mar.
Article in German | MEDLINE | ID: mdl-19156432

ABSTRACT

Leg ulcers may result in serious morbidity in patients with connective tissue diseases and Raynaud's phenomenon (RP). We describe a 35-year-old woman with mixed connective tissue disease who suffered from leg ulcers refractory to iloprost. When the patient was treated with the selective endothelin A receptor antagonist sitaxsentan for pulmonary arterial hypertension, the ulcers improved within 4 weeks and resolved completely thereafter. In addition, severity of RP ameliorated markedly. Further evaluation of sitaxsentan in patients with connective tissue diseases suffering from ischemic skin ulcers is required.


Subject(s)
Isoxazoles/administration & dosage , Leg Ulcer/complications , Leg Ulcer/drug therapy , Raynaud Disease/complications , Raynaud Disease/drug therapy , Scleroderma, Systemic/complications , Scleroderma, Systemic/drug therapy , Thiophenes/administration & dosage , Adult , Antihypertensive Agents/administration & dosage , Female , Humans , Treatment Outcome
4.
Rheumatology (Oxford) ; 48(1): 70-3, 2009 Jan.
Article in English | MEDLINE | ID: mdl-19056798

ABSTRACT

OBJECTIVES: In SSc, diagnosis and classification is based mainly on skin sclerosis. Herein, we investigated in a large multicentre cohort, to what extent skin sclerosis reflects organ involvement and additional clinical symptoms. METHODS: A total of 1200 SSc patients from the register of the German Systemic Sclerosis Network (DNSS), classified as either lcSSc or dcSSc, were analysed for their serological characteristics, clinical symptoms and organ manifestations in relation to skin involvement measured by the modified Rodnan skin score (mRSS). RESULTS: SSc patients with different mRSS did not differ significantly in their disease duration and in most of the clinical symptoms. They showed a similar distribution of most organ manifestations such as pulmonary arterial hypertension as well as cardiac, renal and nervous system involvement. More severe skin thickening was found to be associated with pulmonary fibrosis and gastrointestinal symptoms, as well as with digital ulcers and musculoskeletal involvement. CONCLUSIONS: In patients with SSc, potentially life-threatening complications and clinical symptoms with high impact on the quality of life occur independently from the extent of skin sclerosis. The diagnosis in SSc patients with a low mRSS could be missed or they could be insufficiently treated.


Subject(s)
Scleroderma, Systemic/pathology , Skin/pathology , Cohort Studies , Contracture/etiology , Deglutition Disorders/etiology , Humans , Hypertension, Pulmonary/etiology , Pulmonary Fibrosis/etiology , Scleroderma, Diffuse/complications , Scleroderma, Diffuse/pathology , Scleroderma, Systemic/complications , Severity of Illness Index , Skin Ulcer/etiology , Time Factors
5.
Rheumatology (Oxford) ; 47(8): 1185-92, 2008 Aug.
Article in English | MEDLINE | ID: mdl-18515867

ABSTRACT

OBJECTIVE: Systemic sclerosis (SSc) is a rare, heterogeneous disease, which affects different organs and therefore requires interdisciplinary diagnostic and therapeutic management. To improve the detection and follow-up of patients presenting with different disease manifestations, an interdisciplinary registry was founded with contributions from different subspecialties involved in the care of patients with SSc. METHODS: A questionnaire was developed to collect a core set of clinical data to determine the current disease status. Patients were grouped into five descriptive disease subsets, i.e. lcSSc, dcSSc, SSc sine scleroderma, overlap-syndrome and UCTD with scleroderma features. RESULTS: Of the 1483 patients, 45.5% of patients had lcSSc and 32.7% dcSSc. Overlap syndrome was diagnosed in 10.9% of patients, while 8.8% had an undifferentiated form. SSc sine scleroderma was present in 1.5% of patients. Organ involvement was markedly different between subsets; pulmonary fibrosis for instance was significantly more frequent in dcSSc (56.1%) than in overlap syndrome (30.6%) or lcSSc (20.8%). Pulmonary hypertension was more common in dcSSc (18.5%) compared with lcSSc (14.9%), overlap syndrome (8.2%) and undifferentiated disease (4.1%). Musculoskeletal involvement was typical for overlap syndromes (67.6%). A family history of rheumatic disease was reported in 17.2% of patients and was associated with early disease onset (P < 0.005). CONCLUSION: In this nationwide register, a descriptive classification of patients with disease manifestations characteristic of SSc in five groups allows to include a broader spectrum of patients with features of SSc.


Subject(s)
Scleroderma, Systemic/epidemiology , Adult , Age Distribution , Age of Onset , Aged , Cross-Sectional Studies , Female , Germany/epidemiology , Humans , Male , Medicine , Middle Aged , Registries , Scleroderma, Diffuse/epidemiology , Scleroderma, Diffuse/pathology , Scleroderma, Limited/epidemiology , Scleroderma, Limited/pathology , Scleroderma, Systemic/classification , Scleroderma, Systemic/pathology , Specialization
6.
Z Rheumatol ; 67(4): 334-6, 337-40, 2008 Jul.
Article in German | MEDLINE | ID: mdl-18418613

ABSTRACT

The diagnosis and therapy of systemic sclerosis (SSc) is demanding due to its nature as a multisystem disease and its chronic, severe course. To date, there are no generally accepted recommendations for diagnostic work-up either for the time of initial disease diagnosis or for the regular follow-up clinical examinations and diagnostic procedures required. However, due to recent advances, e.g. in the therapy of pulmonary arterial hypertension, regular examinations may contribute to early recognition and treatment of developing organ involvement. This manuscript describes the recommendations for initial and follow-up organ-specific clinical examinations and diagnostic work-up as compiled and carried out by the German Network for Systemic Scleroderma [Deutsche Netzwerk für systemische Sklerodermie (DNSS)].


Subject(s)
Multiple Organ Failure/diagnosis , Practice Guidelines as Topic , Practice Patterns, Physicians'/standards , Scleroderma, Systemic/diagnosis , Serologic Tests/standards , Germany , Humans , Organ Specificity
SELECTION OF CITATIONS
SEARCH DETAIL
...